Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Decitabine - Janssen-Cilag/Otsuka Pharmaceutical

Drug Profile

Decitabine - Janssen-Cilag/Otsuka Pharmaceutical

Alternative Names: 127716; 2'-deoxy-5-azacytidine; 2353-33-5; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; 5-aza-2'-deoxycytidine; DAC; Dacogen; Decitabine mesylate; Deoxycytidine; Dezocitidine; E-7373; NSC-127716

Latest Information Update: 12 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Indiana University; SuperGen
  • Developer Eisai Co Ltd; European Organisation for Research and Treatment of Cancer; Groupe Francophone des Myelodysplasies; HOVON Foundation; Italian Group for Haematological Diseases; Janssen Pharmaceuticals; Janssen-Cilag; M. D. Anderson Cancer Center; Novartis; Otsuka Pharmaceutical; Sidney Kimmel Cancer Center; Xian-Janssen
  • Class Antineoplastics; Aza compounds; Deoxyribonucleosides; Pyrimidine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
  • Phase III Chronic myelomonocytic leukaemia
  • Phase I/II Malignant melanoma; Ovarian cancer
  • Phase I Myelofibrosis
  • No development reported Solid tumours
  • Discontinued Colorectal cancer

Most Recent Events

  • 09 Jan 2023 Efficacy data from a phase III trial in Acute myeloid leukaemia presented at the 64th American Society of Hematology Annual Meeting and Exposition(ASH-Hem-2023)
  • 16 Aug 2022 European Organisation for Research and Treatment of Cancer (EORTC) in collaboration with Janssen Pharmaceuticals completes phase III trials in Acute myeloid leukemia in Slovakia and Bulgaria before August 2022 (IV)(EudraCT2014-001486-27)
  • 28 Jun 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top